Aaron Berger, M.D.
					Dr. Aaron Berger
Board-Certified Urologist
Chief Medical Officer and Director of Clinical Research
Aaron D. Berger, M.D. earned his Bachelor of Science degree from the University of Wisconsin with a major in biochemistry and molecular biology. Dr. Berger attended medical school at the David Geffen School of Medicine at University of California Los Angeles to earn his M.D. He completed his residency in Urology at the NYU Langone Medical Center in New York. Dr. Berger completed a fellowship at the University of California San Francisco in Laparoscopy, Endourology and Robotic Surgery. Dr. Berger serves on the leadership team and is the current Chief Medical Officer and Director of Clinical Research of Associated Urological Specialists (AUS).
Dr. Berger is a nationally recognized expert in the diagnosis and treatment of prostate cancer and leads our Advanced Prostate Cancer Center. He has extensive experience with prostate cancer biomarkers, genetic testing, daVinci robotic surgery, androgen receptor pathway inhibitors, immunotherapy, and radioligand therapy. Dr. Berger also has expertise and has conducted multiple clinical trials in the treatment of high risk and recurrent bladder cancer. He has extensive experience in the evaluation and treatment of BPH and procedures such as Urolift, Rezum, and Greenlight laser therapy.
Dr. Berger is married and has two daughters and enjoys spending time with his family and traveling as much as possible. He loves skiing, biking, and trying new restaurants. He is an avid sports fan and rowed on the crew team at UW Madison.
Meet Dr. Berger
Education
Fellowship: University of California San Francisco in Laparoscopy, Endourology and Robotic Surgery
Residency: NYU Langone Medical Center in New York, NY
Medical School: David Geffen School of Medicine at UCLA
Undergraduate: University of Wisconsin Madison earning a B.S. with Honors in biochemistry and Molecular Biology
Board-Certification
Office Locations for Dr. Berger
Videos
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
Urology Times
Assessing Risk in NMIBC: A Foundation for Therapy
Urology Times
The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
Urology Times
Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy
GU Oncology Now